APA (7th ed.) Citation

Furukawa, J., Kato, T., Yamasaki, T., Monji, K., Tanaka, T., Tsuchiya, N., . . . Uemura, H. (2025). Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: Subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification. International Journal of Clinical Oncology, 30(4), 749. https://doi.org/10.1007/s10147-024-02655-4

Chicago Style (17th ed.) Citation

Furukawa, Junya, et al. "Real-world Outcomes with Avelumab + axitinib in Patients with Advanced Renal Cell Carcinoma in Japan: Subgroup Analyses from the J-DART2 Study by International Metastatic Renal Cell Carcinoma Database Consortium Risk Classification." International Journal of Clinical Oncology 30, no. 4 (2025): 749. https://doi.org/10.1007/s10147-024-02655-4.

MLA (9th ed.) Citation

Furukawa, Junya, et al. "Real-world Outcomes with Avelumab + axitinib in Patients with Advanced Renal Cell Carcinoma in Japan: Subgroup Analyses from the J-DART2 Study by International Metastatic Renal Cell Carcinoma Database Consortium Risk Classification." International Journal of Clinical Oncology, vol. 30, no. 4, 2025, p. 749, https://doi.org/10.1007/s10147-024-02655-4.